Biologics in refractory idiopathic inflammatory myositis (IIM): What experience in juvenile vs adult myositis tells us about the use of biologics in pediatric IIM

References

• Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011;40(4 Pt 2):e237–e247.
   PubMedGoogle Scholar
• Hornung T, Wenzel J. Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment. Drugs. 2014;74(9):981–98.
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–78.
   PubMed Web of Science ®Google Scholar
• Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38(5):383–92.
   PubMed Web of Science ®Google Scholar
• Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35(2):254–9.
   PubMed Web of Science ®Google Scholar
• Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30(8):1021–8.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762–3.
   PubMed Web of Science ®Google Scholar
• Munoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2013;31(6):896–903.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al., RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.
   PubMed Web of Science ®Google Scholar
• Unger L, Kampf S, Luthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014;53(9):1630–8.
   PubMed Web of Science ®Google Scholar
• Barsotti S, Cioffi E, Tripoli A, Tavoni A, D’Ascanio A, Mosca M, Neri R. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo. 2018;70(2):78–84.
   PubMed Web of Science ®Google Scholar
• Majmudar S, Hall HA, Zimmermann B. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol. 2009;15(7):338–40.
   PubMed Web of Science ®Google Scholar
• Luca NJ, Atkinson A, Hawkins C, Feldman BM. Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab. J Rheumatol. 2012;39(7):1483–5.
   PubMed Web of Science ®Google Scholar
• Basnayake C, Cash K, Blumbergs P, Limaye V. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol. 2015;34(2):371–7.
   PubMed Web of Science ®Google Scholar
• Deligny C, Goëb V, Dueymes M, Kahn V, Dehlinger V, Baptiste GJ, et al. Rituximab for patients with myopathy associated with anti-signal recognition particle antibodies: comment on the article by Valiyil et al. Arthritis Care Res (Hoboken). 2011;63(3):460; author reply 461.
   PubMed Web of Science ®Google Scholar
• Mitchell C, Crayne CB, Cron RQ. Patterns of B cell repletion following rituximab therapy in a pediatric rheumatology cohort. ACR Open Rheumatol. 2019;1(8):527–32.
   PubMedGoogle Scholar
• Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol. 2014;32:689–96.
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.
   PubMed Web of Science ®Google Scholar
• Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol. 2008;26(5):887–93.
   PubMed Web of Science ®Google Scholar
• Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010;62(9):1328–34.
   PubMed Web of Science ®Google Scholar
• Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford). 2009;48(5):594–5.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al., the RIM Study Group. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66(3):740–9.
   PubMed Web of Science ®Google Scholar
• Limaye V, Hissaria P, Liew CL, Koszyka B. Efficacy of rituximab in refractory antisynthetase syndrome. Intern Med J. 2012;42(3):e4–e7.
   PubMed Web of Science ®Google Scholar
• Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017;56(1):26–36.
   PubMed Web of Science ®Google Scholar
• Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, et al., the RIM Study Group. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015;16(1):257.
   PubMedGoogle Scholar
• Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016;55(6):991–9.
   PubMed Web of Science ®Google Scholar
• Lopez De Padilla CM, Crowson CS, Hein MS, Strausbauch MA, Aggarwal R, Levesque MC, Reed AM, et al. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. Clin Exp Rheumatol. 2015;33(5):655–63.
   PubMed Web of Science ®Google Scholar
• Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003;101(11):4464–71.
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465–75.
   PubMed Web of Science ®Google Scholar
• Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford). 2010;49(10):1867–77.
   PubMed Web of Science ®Google Scholar
• Zouali M, Richard Y. Marginal zone B-cells, a gatekeeper of innate immunity. Front Immunol. 2011;2:63.
   PubMed Web of Science ®Google Scholar
• Gupta L, Chaurasia S, Srivastava P, Dwivedi S, Lawrence A, Misra R. Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults. Clin Rheumatol. 2018;37(5):1265–71.
   PubMed Web of Science ®Google Scholar
• Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68(6):836–43.
   PubMed Web of Science ®Google Scholar
• López De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS, et al. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol. 2013;40(3):294–302.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shigemura T, et al. Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol. 2015;42(12):2412–8.
   PubMed Web of Science ®Google Scholar
• Morais SA, Vilas-Boas A, Isenberg DA. B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2015;7(4):122–51.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323–31.
   PubMed Web of Science ®Google Scholar
• Hoffman RW, Merrill JT, Alarcon-Riquelme MM, Petri M, Dow ER, Nantz E, et al. Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol. 2017;69(3):643–54.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D, et al., ADDRESS II Investigators. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70(2):266–76.
   PubMed Web of Science ®Google Scholar
• Kaegi C, Steiner UC, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders. Front Immunol. 2020;11:433.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–15.
   PubMed Web of Science ®Google Scholar
• Lenert A, Niewold TB, Lenert P. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2017; 11:747–57.
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–70.
   PubMed Web of Science ®Google Scholar
• Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002;100(5):1715–20.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(6):1536–44.
   PubMedGoogle Scholar
• Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology. 1996;88(1):13–9.
   PubMed Web of Science ®Google Scholar
• Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Coles AJ, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332–42.
   PubMed Web of Science ®Google Scholar
• Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurol. 2016;16:48.
   PubMed Web of Science ®Google Scholar
• Sá J, Costelha J, Marinho A. Inclusion body myositis treated with alemtuzumab. Eur J Case Rep Intern Med. 2019;6(12):001368.
   PubMedGoogle Scholar
• Ruck T, Bittner S, Kuhlmann T, Wiendl H, Meuth SG. Long-term efficacy of alemtuzumab in polymyositis. Rheumatology (Oxford). 2015;54(3):560–2.
   PubMed Web of Science ®Google Scholar
• Thompson B, Corris P, Miller JAL, Cooper RG, Halsey JP, Isaacs JD. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol. 2008;35(10):2080–2.
   PubMed Web of Science ®Google Scholar
• Reiff A, Shaham B, Weinberg KI, Crooks GM, Parkman R. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis. J Clin Immunol. 2011;31(4):615–22.
   PubMed Web of Science ®Google Scholar
• Aouad P, Yiannikas C, Fernando SL, Parratt J. A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis. Mult Scler J Exp Transl Clin. 2018;4(4):2055217318819012.
   Google Scholar
• Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019;25(12):1605–17.
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43(1):16–24.
   PubMed Web of Science ®Google Scholar
• Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43(10):2368–77.
   PubMedGoogle Scholar
• Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):177–90.
   PubMed Web of Science ®Google Scholar
• Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W, Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2012;32(3):639–43.
   PubMed Web of Science ®Google Scholar
• Pachman LM, Fedczyna TO, Lechman TS, Lutz J. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep. 2001;3(5):379–86.
   PubMedGoogle Scholar
• De Paepe B, Creus KK, De Bleecker JL. The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol. 2012;2012:369432.
   PubMedGoogle Scholar
• Chinoy H, Salway F, John S, Fertig N, Tait BD, Oddis CV, et al., UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology (Oxford). 2007;46(9):1411–6.
   PubMed Web of Science ®Google Scholar
• Lutz J, Huwiler KG, Fedczyna T, Lechman TS, Crawford S, Kinsella TR, Pachman LM. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol. 2002;103(3):260–3.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review . Scientificworldjournal. 2014;2014:179180.
   PubMedGoogle Scholar
• Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr. 2010;157(4):653–7.
   PubMed Web of Science ®Google Scholar
• Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018;47(6):858–64.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65(9):1233–6.
   PubMed Web of Science ®Google Scholar
• Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70:427–36.
   PubMed Web of Science ®Google Scholar
• Tosounidou S, MacDonald H, Situnayake D. Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome. Rheumatology (Oxford). 2014;53(5):960–1.
   PubMed Web of Science ®Google Scholar
• Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29(1):1–19.
   PubMed Web of Science ®Google Scholar
• Liu SW, Velez NF, Lam C, Femia A, Granter SR, Townsend HB, Vleugels RA. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149(10):1204–8.
   PubMed Web of Science ®Google Scholar
• de Souza FH, Barros TB, Levy-Neto M, Shinjo SK. Adalimumab induced-inflammatory myopathy in rheumatoid arthritis. Acta Reumatol Port. 2012;37(2):180–3.
   PubMed Web of Science ®Google Scholar
• Nagashima T, Minota S. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy. J Rheumatol. 2011;38(3):574; author reply 575.
   PubMed Web of Science ®Google Scholar
• Liozon E, Ouattara B, Loustaud-Ratti V, Vidal E. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol. 2007;36(6):484–6.
   PubMed Web of Science ®Google Scholar
• Campanilho-Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, Pilkington CA, for the Juvenile Dermatomyositis Research Group (JDRG). Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22(1):79.
   PubMed Web of Science ®Google Scholar
• Hernandez-Garfella ML, Gracia-Garcia A, Cervera-Taulet E, Garcia-Villanueva C, Montero HJ. Adalimumab for recurrent orbital myositis in Crohn’s disease: report of a case with a 3-year follow-up. J Crohns Colitis. 2011;5(3):265–6.
   PubMed Web of Science ®Google Scholar
• Vadala di Prampero S, Marino M, Toso F, Avellini C, Nguyen V, Sorrentino D. Isolated bilateral gastrocnemius myositis in crohn disease successfully treated with adalimumab. Case Rep Gastroenterol. 2016;10(3):661–7.
   PubMedGoogle Scholar
• Verma S, Kroeker KI, Fedorak RN. Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature. BMC Gastroenterol. 2013;13:59.
   PubMed Web of Science ®Google Scholar
• Adams AB, Kazim M, Lehman TJ. Treatment of orbital myositis with adalimumab (Humira). J Rheumatol. 2005;32(7):1374–5.
   PubMed Web of Science ®Google Scholar
• Ayabe R, Rootman DB, Hwang CJ, Ben-Artzi A, Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014; 30:415–9.
   PubMed Web of Science ®Google Scholar
• Park JK, Yoo HG, Ahn DS, Jeon HS, Yoo WH. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int. 2012;32(11):3587–90.
   PubMed Web of Science ®Google Scholar
• da Silva TC, Zon Pretti F, Shinjo SK. Adalimumab in anti-synthetase syndrome. Joint Bone Spine. 2013;80(4):432.
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol. 2003;50(1):10–5.
   PubMed Web of Science ®Google Scholar
• Uthman I, El-Sayad J. Refractory polymyositis responding to infliximab. Rheumatology (Oxford). 2004;43(9):1198–9.
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670–7.
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014;66(5):783–7.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–51.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90(2):183–5.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol. 2007;143(2):233–6.
   PubMedGoogle Scholar
• Zengin O, Onder ME, Alkan S, Kimyon G, Huseynova N, Demir ZH, et al. Three cases of anti-TNF induced myositis and literature review. Rev Bras Reumatol Engl Ed. 2016;57:590–5.
   PubMedGoogle Scholar
• Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010;29(5):563–6.
   PubMed Web of Science ®Google Scholar
• Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol. 1999;155(2):453–60.
   PubMed Web of Science ®Google Scholar
• Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol. 1999;92(2):161–9.
   PubMed Web of Science ®Google Scholar
• Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve. 2010;41(5):581–92.
   PubMed Web of Science ®Google Scholar
• Herrero-Beaumont G, Martínez Calatrava MJ, Castañeda S. Abatacept mechanism of action: concordance with its clinical profile. Reumatol Clin. 2012;8(2):78–83.
   PubMedGoogle Scholar
• Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis—a case-based review. Clin Rheumatol. 2015;34(3):609–12.
   PubMed Web of Science ®Google Scholar
• Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, Haranaka M, Ishii K. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford). 2014;53(2):379–80.
   PubMed Web of Science ®Google Scholar
• Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine. 2011;78(4):431–2.
   PubMed Web of Science ®Google Scholar
• Tjarnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasova Studynkova J, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77(1):55–62.
   PubMed Web of Science ®Google Scholar
• Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum. 2007;56(2):674–87.
   PubMedGoogle Scholar
• Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73(5):913–20.
   PubMed Web of Science ®Google Scholar
• Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334(1–2):123–5.
   PubMed Web of Science ®Google Scholar
• Svensson J, Holmqvist M, Tjärnlund A, Dastmalchi M, Hanna B, Magnusson Bucher S, Lundberg IE. Use of biologic agents in idiopathic inflammatory myopathies in Sweden: a descriptive study of real life treatment. Clin Exp Rheumatol. 2017;35(3):512–5.
   PubMed Web of Science ®Google Scholar
• Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine. 2008;75(3):366–7.
   PubMed Web of Science ®Google Scholar
• Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol. 2006;176(1-2):9–15.
   PubMed Web of Science ®Google Scholar
• Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009;60(8):2505–12.
   PubMed Web of Science ®Google Scholar
• Yang M, Cen X, Xie Q, Zuo C, Shi G, Yin G. Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis. Clin Dev Immunol. 2013;2013:717808.
   PubMedGoogle Scholar
• Tournadre A, Miossec P. Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep. 2012;14(3):252–6.
   PubMed Web of Science ®Google Scholar
• Murphy SM, Lilleker JB, Helliwell P, Chinoy H. The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. Rheumatology (Oxford). 2016;55(12):2277–8.
   PubMed Web of Science ®Google Scholar
• Beaumel A, Muis-Pistor O, Tebib JG, Coury F. Antisynthetase syndrome treated with tocilizumab. Joint Bone Spine. 2016;83(3):361–2.
   PubMed Web of Science ®Google Scholar
• Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50(7):1344–6.
   PubMed Web of Science ®Google Scholar
• Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford). 2014;53(10):1907–8.
   PubMed Web of Science ®Google Scholar
• Umeda M, Aramaki T, Fujikawa K, Iwamoto N, Ichinose K, Terada K, et al. Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis. Int J Rheum Dis. 2017;20(11):1868–71.
   PubMed Web of Science ®Google Scholar
• Raine C, Hamdulay SS, Khanna M, Boyer L, Kinderlerer A. An unusual complication of tocilizumab therapy: MRI appearances of thenar eminence pyomyositis. Joint Bone Spine. 2013;80(2):222.
   PubMed Web of Science ®Google Scholar
• Notarnicola A, Lapadula G, Natuzzi D, Lundberg IE, Iannone F. Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. Scand J Rheumatol. 2015;44(3):224–8.
   PubMed Web of Science ®Google Scholar
• Moran EM, Mastaglia FL. The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul Disord. 2014;24(11):943–52.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019;58(6):1011–5.
   PubMed Web of Science ®Google Scholar
• Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, Vleugels RA. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–5.
   PubMed Web of Science ®Google Scholar
• Navarro-Navarro I, Jiménez-Gallo D, Rodríguez-Mateos ME, Rodríguez-Hernández C, Linares-Barrios M. Treatment of refractory anti-NXP2 and anti-TIF1γ dermatomyositis with tofacitinib. J Dtsch Dermatol Ges. 2020.
   PubMed Web of Science ®Google Scholar
• Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59.
   PubMedGoogle Scholar
• Landon-Cardinal O, Benveniste O, Allenbach Y. Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e60.
   PubMedGoogle Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291–3.
   PubMed Web of Science ®Google Scholar
• John Hopkins University. Study of Tofacitinib in Refractory Dermatomyositis (STIR). 2017 [cited 2020 Oct 09]. Available from: https://clinicaltrials.gov/ct2/show/NCT03002649?term=Tofacitinib&cond=dermatomyositis&draw=2&rank=1
   Google Scholar
• Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib – a report of two cases. J Autoimmun. 2019;100:131–6.
   PubMed Web of Science ®Google Scholar
• Safina BS, Baker S, Baumgardner M, Blaney PM, Chan BK, Chen YH, et al. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. J Med Chem. 2012;55(12):5887–900.
   PubMed Web of Science ®Google Scholar